Protein Degradation in Cancer: PROTACs and Targeted Degraders for Previously Difficult-to-Drug Targets

Abstract

The development of novel therapeutic strategies targeting protein degradation has revolutionized cancer drug discovery, particularly for proteins previously considered undruggable by conventional small-molecule inhibitors. Proteolysis-targeting chimeras (PROTACs) and other targeted degraders leverage the cell’s endogenous ubiquitin-proteasome system to selectively degrade disease-driving proteins, offering a paradigm shift in oncologic therapeutics. This review critically appraises the scientific rationale, mechanisms, clinical implications, and current state of PROTACs and related technologies, with a focus on their role in overcoming limitations of traditional drug modalities and expanding the arsenal against refractory malignancies.

Introduction

The landscape of cancer therapeutics has evolved dramatically, yet a significant proportion of oncogenic proteins remain intractable to traditional small-molecule or antibody-based inhibition. This challenge stems from the structural features of many cancer-associated proteins, such as lack of accessible binding pockets or intrinsically disordered regions. Protein degradation strategies, particularly the use of PROTACs (Proteolysis-Targeting Chimeras), have emerged as a groundbreaking approach to target these proteins for elimination rather than inhibition. The mechanism harnesses the cell’s ubiquitin-proteasome pathway, offering new hope for patients with tumors reliant on proteins previously deemed undruggable. This review synthesizes recent evidence, mechanistic insights, and clinical progress in protein degradation therapeutics in oncology.

Epidemiology / Disease Burden

Cancer remains the second leading cause of mortality worldwide, accounting for nearly 10 million deaths annually. Despite advances in early detection and targeted therapies, a substantial subset of patients presents with or develops tumors driven by proteins that are not amenable to current drug modalities. These include transcription factors (e.g., c-Myc), scaffold proteins, and mutant variants lacking druggable domains. The inability to effectively target these proteins contributes to poor clinical outcomes, resistance to standard therapies, and underscores the urgent need for novel approaches such as targeted protein degradation.

Pathophysiology

Oncogenesis is frequently driven by aberrant expression or function of proteins critical for cell proliferation, survival, and resistance to apoptosis. Many such oncogenic drivers, including certain kinases, transcription factors, and epigenetic regulators, lack classical active sites or display high sequence homology to normal proteins, limiting the selectivity and efficacy of inhibitors. The ubiquitin-proteasome system (UPS) is the cell’s primary machinery for regulated protein turnover, maintaining proteostasis through targeted degradation. PROTACs and related degraders exploit this system by recruiting E3 ubiquitin ligases to tag pathogenic proteins for destruction, thereby modulating signaling pathways at the level of protein abundance rather than enzymatic inhibition.

Risk Factors

Patients at risk for cancers driven by traditionally undruggable targets often harbor specific genetic alterations, such as gene fusions, amplifications, or point mutations that result in abnormal protein accumulation or function. Environmental factors, family history, and prior exposure to genotoxic agents can predispose individuals to such malignancies. Furthermore, the emergence of acquired resistance to standard therapies can result in clonal selection of tumor cells highly dependent on proteins that escape conventional pharmacological targeting, thus necessitating alternative therapeutic strategies like protein degraders.

Clinical Features

Cancers associated with difficult-to-drug proteins present with a heterogeneous array of clinical manifestations depending on the tissue of origin and molecular subtype. Common features include aggressive tumor growth, early metastasis, poor differentiation, and resistance to standard-of-care therapies. The clinical course is often marked by rapid progression, limited response to existing drugs, and a high rate of relapse, highlighting the need for innovative treatment modalities that can address underlying molecular drivers.

Diagnosis

Diagnosis of cancers involving undruggable targets relies on a combination of histopathology, molecular profiling, and advanced genomic techniques such as next-generation sequencing (NGS) and transcriptomic analysis. These tools enable the identification of specific mutations, gene rearrangements, and protein expression patterns that inform prognosis and guide therapeutic decision-making. The identification of actionable targets for protein degradation is increasingly incorporated into precision oncology workflows, with companion diagnostics being developed to optimize patient selection for degrader-based therapies.

Treatment & Management

Traditional management strategies include surgery, radiotherapy, chemotherapy, and targeted therapies such as kinase inhibitors and monoclonal antibodies. However, the efficacy of these modalities is limited when the oncogenic driver lacks a suitable binding site for inhibition. The advent of protein degradation technologies, particularly PROTACs, offers a complementary approach. PROTACs are heterobifunctional molecules comprising a ligand for the target protein, a linker, and a ligand for an E3 ubiquitin ligase. Upon binding, the PROTAC facilitates ubiquitination and subsequent proteasomal degradation of the target protein. This approach has expanded therapeutic options for previously refractory malignancies and is being actively explored in both preclinical and clinical settings.

Recent Advances / Emerging Therapies

The last decade has witnessed remarkable progress in the development of PROTACs and related degraders. Notably, several PROTACs targeting androgen receptor (AR), estrogen receptor (ER), and Bruton's tyrosine kinase (BTK) have advanced into clinical trials for prostate cancer, breast cancer, and hematologic malignancies, respectively. For instance, ARV-110 and ARV-471 have shown promising activity in early-phase trials, including in patients with resistance to standard therapies. The chemical versatility of PROTACs allows the targeting of proteins involved in transcription, epigenetic regulation, and other non-enzymatic functions. Emerging modalities such as molecular glues and autophagy-targeting chimeras (AUTACs) further expand the degradome, offering new avenues for targeting diverse oncogenic proteins.

Guideline Recommendations

While no PROTAC-based therapies have yet received regulatory approval, leading oncology guidelines emphasize the importance of clinical trial enrollment for patients with tumors harboring undruggable targets. Precision oncology programs increasingly advocate for comprehensive molecular profiling to identify suitable candidates for protein degradation strategies. Consensus statements from expert panels highlight the potential utility of degraders for overcoming therapeutic resistance and recommend their consideration in refractory disease settings where conventional options have been exhausted.

Conclusion

Protein degradation technologies, particularly PROTACs and related modalities, represent a transformative advance in the armamentarium against cancer, enabling the targeting of proteins once considered beyond the reach of pharmacological intervention. By leveraging the cell’s own proteolytic systems, these therapies offer the potential for deeper and more durable responses, especially in malignancies driven by undruggable proteins. Continued research into degrader design, mechanism of action, clinical efficacy, and safety will be critical to realizing their full therapeutic potential and integrating them into standard oncologic care.